Solbec completes Phase I psoriasis trial
Wednesday, 09 February, 2005
Solbec Pharmaceuticals (ASX: SBP) has announced successful completion of its Phase I study of its devil's apple-derived drug Coramsine as a treatment for psoriasis.
Preliminary results from the trial, which incorporated two stages to look at the safety and tolerability in healthy individuals, plus a third stage to assess efficacy in ten patients with psoriasis, indicate that there were no treatment-related adverse events during the trial. The drug was administered in a cream formulation and in the efficacy stage of the trial, was compared to both placebo and to a standard treatment for psoriasis over a period of 56 days.
The company said efficacy results would be reported in the second quarter of this year, once the trial has been unblinded and data analysed.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...